Leila A. Pak

Leila A. Pak

Auto-generated profile, based on publicly available information

Leila A. Pak

National Medical Research Center for Children’s Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2019 in Russian Pediatric Journal
Verified
Journal Article
Open access
LPLeila A. Pak
Leila A. Pak
KZK. V. Zherdev
K. V. Zherdev
LKL. M. Kuzenkova
L. M. Kuzenkova
AKA. L. Kurenkov
A. L. Kurenkov
BBB. I. Bursagova
B. I. Bursagova
In the article the authors consider such methods of the alternative/complementary treatment of the cerebral palsy (CP), presented in the modern domestic and foreign literature, as metabolic (amino acid composites), metamer (I.A. Skvortsov), intravenous administration of baclofen, antiepileptic (vagal stimulation, levetiracetam), acupuncture, transcranial cerebral micropolarization, epidural stimulation, modified motion-induced restriction therapy (MMIRT), stem cell therapy, as well as some other complementary/palliative approaches to the correction of clinical manifestations of various forms of CP. The final part of the article presents the attitude of modern evidence-based medicine to the main methods of the alternative/complementary treatment of cerebral palsy. These data are based almost exclusively on international systematic reviews and relevant meta-analyses.

30 September 2021 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Closed access
PDF file
AKAleksey L. Kurenkov
Aleksey L. Kurenkov
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
LPLale A. Pak
Lale A. Pak
BBBella I. Bursagova
Bella I. Bursagova
TPTatyana V. Podkletnova
Tatyana V. Podkletnova
KSKirill Savostyanov
Kirill Savostyanov
Duchenne muscular dystrophy (DMD) is a disease with an X-linked recessive type of inheritance, belonging to a group of disorders with primary muscle damage, caused by pathogenic variants in the DMD gene and associated with dysfunction of the dystrophin protein. Since DMD is manifested by the gradual development of progressive, mainly proximal muscle weakness, the differential diagnosis is primarily carried out in the group of diseases with muscle damage - myopathies. Among these diseases, the leading candidates for differential diagnosis are hereditary myopathies (limb-girdle muscular dystrophies, facioscapulohumeral dystrophy, congenital muscular dystrophies, glycogenoses - the most common juvenile form of glycogenosis type II (Pompe disease)) and, much less often, congenital myopathies and other conditions of neuromuscular diseases). When conducting a differential diagnosis in a child with suspected DMD, the age of the onset of the disease, early initial clinical manifestations and the development of symptoms as they grow, genealogical analysis, laboratory tests (the level of creatine kinase, aspartate aminotransferase, alanine aminotransferase in blood serum), instrumental (electromyography, magnetic resonance imaging of the brain and muscles) and molecular genetics (polymerase chain reaction, multiplex ligation-dependent probe amplification, next-generation sequencing, Sanger sequencing, etc.) of studies, and in some cases, muscle biopsy data. Knowledge of the nuances of the differential diagnosis allows establishing a genetic diagnosis of DMD as early as possible, which is extremely important for the formation of the prognosis of the disease and the implementation of all available treatment methods, including pathogenetic therapy, and is also necessary for medical and genetic counselling of families with DMD patients.

25 December 2021 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Closed access
PDF file
ТПТатьяна Владимировна Подклетнова
Татьяна Владимировна Подклетнова
OKOlga B. Kondakova
Olga B. Kondakova
EUEugeniya V. Uvakina
Eugeniya V. Uvakina
DFDariya A. Fisenko
Dariya A. Fisenko
ALAnastasiya A. Lyalina
Anastasiya A. Lyalina
АЛА. С. Лялина
А. С. Лялина
Duchenne muscular dystrophy (DMD) is a hereditary progressive muscular dystrophy, mainly manifested in boys, is characterized by the onset at an early age, gradual symmetrical atrophy of the striated musculature of the limbs, trunk, as well as damage to the heart muscle. As a rule, girls and women inheriting a pathological mutation are classified only as its carriers and do not have clinical manifestations of the disease. Rare cases when women or girls show clinical manifestations of DMD may be due to chromosomal rearrangements involving the region of the short arm of the X chromosome (Xp21.2), deletions of this region, complete loss of the X chromosome (Shereshevsky-Turner syndrome), homogenous X chromosome dysomnia, compound heterozygous state for two pathogenic mutations in the DMD gene, nonequilibrium inactivation of the X chromosome. When female mutation carriers have DMD clinical symptoms, they usually manifest much milder than boys and young males. Descriptions of patients with the severe course and rapid progression of the disease, comparable in the rate of progression with boys, are rare. In this article, the authors share their experience of observing a girl patient who suffered from a severe form of DMD.

26 December 2020 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
TPTatyana V. Podkletnova
Tatyana V. Podkletnova
LPLale A. Pak
Lale A. Pak
OEOksana A. Ereshko
Oksana A. Ereshko
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an inherited chronic progressive lysosomal disease associated with recessive X-linked inheritance. MPS II is classified as an orphan disease and occurs at a rate of 1.3 per 100,000 white boys. Hunter syndrome is the most common type of mucopolysaccharidosis, accounting for about 50% of MPS types. The diseases pathogenesis is based on a violation of the stepwise cleavage of glycosaminoglycans (GAG) heparansulfate and dermatansulfate caused by a deficiency of the iduronate-2-sulfatase enzyme encoded by theIDSgene. The existing deficiency or complete absence of iduronate-2-sulfatase leads to a violation of the final stage of glycosaminoglycan catabolism and the accumulation heparansulfate and dermatansulfate in all organs and tissues. Currently, there are two drugs registered in the Russian Federation for pathogenetic enzyme replacement therapy of MPS: idursulfase and idursulfase beta. This refers to the expansion of the therapeutic options for Hunter syndrome patients in the event of severe adverse events. It allows choosing the treatment regimen that will be optimal for the patient and will significantly improve the quality of life. In this article, the authors share their own experience of changing enzyme replacement therapy in an MPS II child patient.

26 December 2020 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
LPLale A. Pak
Lale A. Pak
OKOlga B. Kondakova
Olga B. Kondakova
ALAnastasia A. Lyalina
Anastasia A. Lyalina
PTPolina Tsygankova
Polina Tsygankova
NLNatalia V. Lapshina
Natalia V. Lapshina
Infantile parkinsonism-dystonia, type 1 (DTDS) (OMIM 613135) is a rare inherited autosomal recessive disease that manifests in infancy. The development of the disease is caused by a homozygous or compound-heterozygous mutation in theSLC6A3gene (OMIM 126455), which encodes a dopamine Transporter localized on the short arm of chromosome 5 (5p15). The main pathogenetic mechanism of the disease is the loss of the function of the main dopamine transporter at the presynaptic level, which leads to a decrease in the reuptake of dopamine in the synaptic cleft, depletion of presynaptic dopamine reserves, and an increase in the amount of extraneuronal dopamine. Currently, there are 20 cases of this disease in children in the world. The main clinical manifestations of DTDS are various hyperkinesis patterns (dystonia, chorea, athetosis, etc.), followed by hypokinesia and rigidity, developing against the background of axial hypotension. Difficulties in differential diagnosis lead to the fact that many patients are observed for years with erroneous clinical diagnoses, including cerebral palsy, regularly receiving rehabilitation treatment without clinical effect. The mentioned above explains the need for clinicians to be aware of a rare disease DTDS, which will avoid diagnostic errors, prescribe adequate therapy promptly, and thereby significantly improve the quality of life of patients and their families. The article contains an overview of the etiological, pathogenetic, epidemiological, diagnostic, and therapeutic aspects of DTDS. For the first time in Russia, there is reported a clinical case of this rare disease, which presents the own experience with DTDS patient.

30 March 2022 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Closed access
PDF file
ЛПЛолита Алиевна Пак
Лолита Алиевна Пак
KSKirill Savostyanov
Kirill Savostyanov
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
APAleksander Pushkov
Aleksander Pushkov
IZIlya Sergeevich Zhanin
Ilya Sergeevich Zhanin
EUEugeniya V. Uvakina
Eugeniya V. Uvakina
Introduction. Speech disorders (SD) are one of the urgent problems of childhood neurology. Despite the long history of studying speech disorders in children, the use of modern instrumental research in the diagnosis, the use of various therapeutic techniques for their correction, scientific interest in understanding the pathogenetic foundations of these disorders remains relatively high. In recent years, much attention has been paid to studying the genetic causes of the development of this pathology. Currently, data are presented on more than 20 candidate genes that may determine isolated speech disorders or their combination with other cognitive disorders. The study of the molecular and genetic foundations of speech disorders in children will expand clinicians’ understanding of the pathogenesis of speech disorders and optimize diagnostic approaches. The aim of the study is to investigate the structure of SD and diseases and to define clinically significant nucleotide variants leading to various diseases, the phenotype of which includes SD. Materials and methods. One hundred sixty 2 to 7-year children with speech disorders aged were under observation, 93 (58.1%) girls and 67 (41.9%) boys were hospitalized into the Department of Neuropsychiatry and psychosomatic pathology and the Department of Pathology of early Childhood of the of National Medical Research Center for Children’s Health of the Ministry of Health of Russian Federation. All observed patients underwent sequencing of the clinical exome by mass parallel sequencing. Results. Sequencing the clinical exome in SD children makes it possible to detect clinically significant nucleotide variants leading to various diseases, including speech disorders. The most common speech disorders in children are clinical manifestations of hereditary diseases. In 5 (3.1%) of the observed patients, nucleotide variants were found during a molecular genetic study that can cause diseases in which speech and intellectual-mnestic disorders are among the main clinical manifestations. Conclusion. There were studied molecular genetic features of speech disorders in 160 children. The continuation of clinical studies aimed at searching for pathogenic genome variants leading to speech and intellectual-mnestic disorders in a representative sample of patients with speech disorders will resolve the issue of the feasibility of including sequencing of the clinical exome in the diagnostic algorithm of speech disorders in children.